Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 107

1.

Synergistic effect of liver X receptor activation and simvastatin on plaque regression and stabilization: an magnetic resonance imaging study in a model of advanced atherosclerosis.

Giannarelli C, Cimmino G, Connolly TM, Ibanez B, Ruiz JM, Alique M, Zafar MU, Fuster V, Feuerstein G, Badimon JJ.

Eur Heart J. 2012 Jan;33(2):264-73. doi: 10.1093/eurheartj/ehr136. Epub 2011 May 23.

2.

Rapid change in plaque size, composition, and molecular footprint after recombinant apolipoprotein A-I Milano (ETC-216) administration: magnetic resonance imaging study in an experimental model of atherosclerosis.

Ibanez B, Vilahur G, Cimmino G, Speidl WS, Pinero A, Choi BG, Zafar MU, Santos-Gallego CG, Krause B, Badimon L, Fuster V, Badimon JJ.

J Am Coll Cardiol. 2008 Mar 18;51(11):1104-9. doi: 10.1016/j.jacc.2007.09.071. Erratum in: J Am Coll Cardiol. 2008 Apr 15;51(15):1525.

3.

Prostaglandin E1 dose-dependently promotes stability of atherosclerotic plaque in a rabbit model.

Bai W, Zheng X, Zhou L, Li H.

Can J Physiol Pharmacol. 2012 Feb;90(2):131-9. doi: 10.1139/y11-115. Epub 2012 Feb 6.

PMID:
22309388
5.
6.

Ezetimibe reduces plaque inflammation in a rabbit model of atherosclerosis and inhibits monocyte migration in addition to its lipid-lowering effect.

Gómez-Garre D, Muñoz-Pacheco P, González-Rubio ML, Aragoncillo P, Granados R, Fernández-Cruz A.

Br J Pharmacol. 2009 Apr;156(8):1218-27. doi: 10.1111/j.1476-5381.2008.00091.x. Epub 2009 Feb 16.

7.

Synthetic LXR agonist inhibits the development of atherosclerosis in New Zealand White rabbits.

Honzumi S, Shima A, Hiroshima A, Koieyama T, Terasaka N.

Biochim Biophys Acta. 2011 Dec;1811(12):1136-45. doi: 10.1016/j.bbalip.2011.08.009. Epub 2011 Aug 19.

PMID:
21875689
8.

Traditional Chinese medication Tongxinluo dose-dependently enhances stability of vulnerable plaques: a comparison with a high-dose simvastatin therapy.

Zhang L, Liu Y, Lu XT, Wu YL, Zhang C, Ji XP, Wang R, Liu CX, Feng JB, Jiang H, Xu XS, Zhao YX, Zhang Y.

Am J Physiol Heart Circ Physiol. 2009 Dec;297(6):H2004-14. doi: 10.1152/ajpheart.00208.2009. Epub 2009 Oct 2.

9.

Recombinant HDL(Milano) exerts greater anti-inflammatory and plaque stabilizing properties than HDL(wild-type).

Ibanez B, Giannarelli C, Cimmino G, Santos-Gallego CG, Alique M, Pinero A, Vilahur G, Fuster V, Badimon L, Badimon JJ.

Atherosclerosis. 2012 Jan;220(1):72-7. doi: 10.1016/j.atherosclerosis.2011.10.006. Epub 2011 Oct 12.

PMID:
22030095
11.

LXR agonist suppresses atherosclerotic lesion growth and promotes lesion regression in apoE*3Leiden mice: time course and mechanisms.

Verschuren L, de Vries-van der Weij J, Zadelaar S, Kleemann R, Kooistra T.

J Lipid Res. 2009 Feb;50(2):301-11. doi: 10.1194/jlr.M800374-JLR200. Epub 2008 Aug 30.

12.

Effects of simvastatin on NF-kappaB-DNA binding activity and monocyte chemoattractant protein-1 expression in a rabbit model of atherosclerosis.

Yang X, Wang L, Zeng H, Dubey L, Zhou N, Pu J.

J Huazhong Univ Sci Technolog Med Sci. 2006;26(2):194-8.

PMID:
16850745
13.

Effect of Si-Miao-Yong-An on the stability of atherosclerotic plaque in a diet-induced rabbit model.

Peng L, Li M, Xu YZ, Zhang GY, Yang C, Zhou YN, Li LJ, Zhang JP.

J Ethnopharmacol. 2012 Aug 30;143(1):241-8. doi: 10.1016/j.jep.2012.06.030. Epub 2012 Jun 28.

PMID:
22750436
14.

[Effects of atorvastatin, fluvastatin, pravastatin, and simvastatin on endothelial function, lipid peroxidation, and aortic atherosclerosis in hypercholesterolemic rabbits].

Jorge PA, Almeida EA, Ozaki MR, Jorge M, Carneiro A.

Arq Bras Cardiol. 2005 Apr;84(4):314-9. Epub 2005 May 2. Portuguese.

15.

Statin therapy alone and in combination with an acyl-CoA:cholesterol O-acyltransferase inhibitor on experimental atherosclerosis.

Worthley SG, Helft G, Corti R, Worthley MI, Chew DP, Fayad ZA, Zaman AG, Fallon JT, Fuster V, Badimon JJ.

Pathophysiol Haemost Thromb. 2007;36(1):9-17. doi: 10.1159/000112634. Epub 2008 Mar 6.

PMID:
18332609
16.

Elimination of macrophages drives LXR-induced regression both in initial and advanced stages of atherosclerotic lesion development.

van der Stoep M, Li Z, Calpe-Berdiel L, van der Sluis RJ, Saleh P, McKinnon HJ, Smit MJ, Korporaal SJ, Van Berkel TJ, Van Eck M, Hoekstra M.

Biochem Pharmacol. 2013 Dec 1;86(11):1594-602. doi: 10.1016/j.bcp.2013.09.019. Epub 2013 Oct 2.

PMID:
24095721
17.

Liver X receptors as potential therapeutic targets in atherosclerosis.

Zhu Y, Li Y.

Clin Invest Med. 2009 Oct 1;32(5):E383-94. Review.

PMID:
19796580
18.

Macrophage liver X receptor is required for antiatherogenic activity of LXR agonists.

Levin N, Bischoff ED, Daige CL, Thomas D, Vu CT, Heyman RA, Tangirala RK, Schulman IG.

Arterioscler Thromb Vasc Biol. 2005 Jan;25(1):135-42. Epub 2004 Nov 11.

19.

Liver X receptor agonist T0901317 reduces atherosclerotic lesions in apoE-/- mice by up-regulating NPC1 expression.

Ou X, Dai X, Long Z, Tang Y, Cao D, Hao X, Hu Y, Li X, Tang C.

Sci China C Life Sci. 2008 May;51(5):418-29. doi: 10.1007/s11427-008-0054-4.

PMID:
18785587
20.

Antihypercholesterolemic and antioxidant efficacies of zerumbone on the formation, development, and establishment of atherosclerosis in cholesterol-fed rabbits.

Hemn HO, Noordin MM, Rahman HS, Hazilawati H, Zuki A, Chartrand MS.

Drug Des Devel Ther. 2015 Aug 3;9:4173-208. doi: 10.2147/DDDT.S76225. eCollection 2015.

Items per page

Supplemental Content

Write to the Help Desk